Both GLP-1 RA and SGLT2i are recognized as glucose-lowering medications able to reduce the risk of MACE in patients with established CV disease or at high CV risk: more in detail, GLP-1 RA seems to have more vascular protection, thus preventing atherosclerosis progression, while SGLT2i are mostly active on hemodynamic status thus preventing hospitalization for heart failure [158]. This evidence concerns the gene GLP1R and heart failure.